MeSsAGe risk score: tool for renal biopsy decision in steroid-dependent nephrotic syndrome

Pediatr Res. 2019 Mar;85(4):477-483. doi: 10.1038/s41390-019-0277-z. Epub 2019 Jan 15.

Abstract

Background: A lack of consensus exists as to the timing of kidney biopsy in children with steroid-dependent nephrotic syndrome (SDNS) where minimal change disease (MCD) predominates. This study aimed at examining the applicability of a biomarker-assisted risk score model to select SDNS patients at high risk of focal segmental glomerulosclerosis (FSGS) for biopsy.

Methods: Fifty-five patients with SDNS and biopsy-proven MCD (n = 40) or FSGS (n = 15) were studied. A risk score model was developed with variables consisting of age, sex, eGFR, suPAR levels and percentage of CD8+ memory T cells. Following multivariate regression analysis, total risk score was calculated as sum of the products of odds ratios and corresponding variables. Predictive cut-off point was determined using receiver operator characteristics (ROC) curve analysis.

Results: Plasma suPAR levels in FSGS patients were significantly higher, while percentage of CD45RO+CD8+CD3+ was significantly lower than in MCD patients and controls. ROC analysis suggests the risk score model with threshold score of 16.7 (AUC 0.84, 95% CI 0.72-0.96) was a good predictor of FSGS on biopsy. The 100% PPV cut-off was >24.0, while the 100% NPV was <13.3.

Conclusion: A suPAR and CD8+ memory T cell percentage-based risk score model was developed to stratify SDNS patients for biopsy and for predicting FSGS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-Inflammatory Agents / therapeutic use*
  • Biopsy*
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Female
  • Glomerulosclerosis, Focal Segmental / etiology
  • Glomerulosclerosis, Focal Segmental / pathology*
  • Humans
  • Kidney / pathology*
  • Lymphocyte Subsets
  • Male
  • Nephrotic Syndrome / complications
  • Nephrotic Syndrome / etiology
  • Nephrotic Syndrome / pathology*
  • Prednisolone / therapeutic use*
  • Receptors, Urokinase Plasminogen Activator / blood
  • Risk Assessment

Substances

  • Anti-Inflammatory Agents
  • Receptors, Urokinase Plasminogen Activator
  • Prednisolone